Financings in Brief: Ventana Medical Systems
This article was originally published in The Gray Sheet
Executive Summary
Ventana Medical Systems: Instrument and reagent manufacturer files registration statement with SEC for a secondary offering of 2.9 mil. shares, including 1.9 mil. to be sold by the company and 1 mil. by selling shareholders. Net proceeds from the offering will go toward "general corporate purposes, which may include expansion of sales and marketing activities, research and development, clinical trials, capital expenditures, repayment of indebtedness and working capital." Dillon, Read & Co. will serve as lead managers for the offering; Bear, Stearns and Cowen & Company are co-managers. Underwriters have an over-allotment option covering 427,500 additional shares, which would be sold by shareholders...
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.